Abstract
Background
Clinician reporting of symptomatic adverse events (AEs) in phase I trials uses the Common Terminology Criteria for Adverse Events (CTCAE). The utility of the patient-reported ...outcomes (PROs) version of the CTCAE (PRO-CTCAE) in this setting is unknown. This prospective, observational study compared patient- and clinician-reported symptomatic AEs in phase I patients.
Methods
Phase I study–eligible patients at Princess Margaret were surveyed with the PRO-CTCAE full-item library (78 symptomatic AEs) at baseline (BL), mid-cycle 1, and mid-cycle 2 (C2). Patient and trial characteristics, best response, and survival data were collected. Presence or absence of patient- (PRO-CTCAE) or clinician-reported symptomatic AEs were compared (kappa) at defined timepoints and overall (BL+ mid-cycle 1 + C2).
Results
Of 292 patients approached from May 2017 to January 2019, a total of 265 (90.8%) were consented, with 243 (91.7%) evaluable and 552 PRO-CTCAE surveys (completion rate = 98.7%) included in analyses. Evaluation of overall patient-reported symptomatic AEs identified 50 PRO-CTCAE and 11 CTCAE items with 10% or greater reporting frequency. Nineteen CTCAE items were reported as 1% or less despite matched PRO-CTCAE items reporting as 10% or greater. Underreported categories included sexual health, bodily emissions, and cognition. Clinician- relative to patient-reporting frequency (ratio) demonstrated 9 symptomatic AEs with a 50-fold or more lower clinician reporting rate. Overall patient–clinician agreement for individual symptomatic AEs ranged from poor (κ = 0.00-0.19) to moderate (κ = 0.40-0.59), with discordance driven by lack of clinician reporting. Dyspnea (κ = 0.54) and peripheral neuropathy (κ = 0.63) at BL and limb edema (κ = 0.55) at C2 demonstrated the highest patient–clinician agreement.
Conclusions
Poor to moderate patient–clinician agreement for symptomatic AEs suggests clinician underreporting in phase I trials. Analyses of severity and interference PRO categories are ongoing.
This study evaluated the effects of a staff training package on the frequency (rate) of trial presentations to children diagnosed with autism. The training consisted of a combination of repeated ...timings, modeling plus frequency building, and modeling in vivo with the client plus frequency building. The experimenters implemented 20-min training sessions or frequency-building sessions with staff that used 1-min timings for trial presentation in each phase. Training resulted in a higher frequency of trials across all 3 participants in the modeling and feedback phase.
Venous thromboembolism (VTE) is being increasingly recognized in children with sickle cell disease (SCD). In a retrospective cohort study, we identified bilateral central venous catheter (CVC) ...placement as an independent risk factor for VTE. At our institution, the only indication for bilateral CVC placement in children with SCD is erythrocytapheresis. To investigate the impact of erythrocytapheresis on coagulation, we measured levels of natural anticoagulants in 11 patients with SCD on chronic erythrocytapheresis, immediately before and after apheresis. We demonstrated a statistically significant reduction in most parameters. Additional studies are needed to further investigate the exact etiology and clinical impact of this acute decrease.
Background :Wernicke’s encephalopathy (WE) is an acute neuropsychiatric syndrome resulting from thiamine deficiency. This neurological deterioration is potentially dangerous because it predisposes the ...patient to hypothermia and decreased immunity. Cancer patients are at high risk of WE due to chronic malnutrition, chemotherapy-induced nausea and vomiting, and consumption of thiamine by rapidly growing tumors. Very little published research addresses the risk of WE in patients with myeloproliferative neoplasm (MPN).
Objectives: To estimate the incidence of WE among patients with MPN, and compare it with those without MPN.
Methods: Patients with a diagnosis of MPN, including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) were identified from 1/1/2003 to 03/31/2013 using the US MarketScan database. The control cohort consisted of a random sample matched to the MPN cohort by age and gender in a 1:1 ratio. Diagnosis of WE was ascertained using ICD-9-CM 265.0, 265.1, 291.1, 294.0 or J code J3411. The two study cohorts were followed for WE from the index date. Cox proportional hazards modeling was used to compare the rates between two cohorts and also control for confounding variables.
Results: A total of 39,761 MPN patients, including PV (51%), ET (42%), post-PV MF (0.2%), post-ET MF (1%), and PMF (2.8%) were identified. Approximately 27% of them were > 65 years of age, and 51% were male. Patients with MPN had higher rates of WE, compared to those without MPN (MPN vs. non-MPN: 1.09 vs. 0.39/1000 person-year, hazard ratio = 2.19, 95% confidence interval 1.43-3.34). The incidence rate of WE was higher in males (male vs. female: 0.93 vs. 0.55/1000 person-year). No specific pattern was observed in age subgroups for both cohorts (e.g. MPN: age <18 vs. 18-39 vs. 40-49 vs. 50-59 vs. 60-69 vs. >70 = 0 vs. 0.85 vs. 1.09 vs. 1.16 vs. 0.72 vs. 0.86/1000 person-year).
Conclusions: Patients with MPN had higher incidence rates of WE, compared to those without MPN. Given the potentially dangerous outcomes associated with WE, physicians who care for patients with MPN should be aware of the risk of WE in this population.
Wu:Sanofi: Employment. Mirza:Sanofi: Employment. Partisano:Sanofi: Employment. Gallagher:Sanofi: Postdoctoral Fellow Other. Vaze:Sanofi: Employment. Zhang:Sanofi: Employment. Gallagher:Sanofi: Employment. Lin:Sanofi: Employment. Juhaeri:Sanofi: Employment.
Introduction
The rate of venous thrombo-embolism (VTE) in patients with sickle cell disease (SCD) is estimated to be 4 - 8%; the incidence of catheter-associated VTE in this cohort is 0.16-0.99 per ...1000 catheter days. Possible mechanisms for VTE in patients with SCD include hyperviscosity, ischemia reperfusion injury and chronic vascular inflammation. Additionally, patients with SCD exhibit decreased plasma levels of natural anticoagulants such as proteins C and S compared to healthy adults. A retrospective review at our institution found that the incidence of central venous line (CVL)-associated VTE in children with SCD was 0.12/1000 catheter days. On multivariate analysis, CVLs were identified as the only independent risk factor for VTE. Among patients with CVL, we found an association between bilateral CVLs and VTE (Odds Ratio 95% CI = 10.3 1.1-92.2). Children with SCD frequently require CVLs for intravenous access or chronic erythrocytapharesis to reduce SCD-related complications. It is unknown, however, if erythrocytapharesis may also disrupt their natural anticoagulants levels and further increase their risk for subsequent VTE. We hypothesized that erythrocytapheresis may contribute to the pro-coagulant phenotype by altering patients' natural anticoagulants levels.
Methods
As part of a quality improvement initiative we measured antithrombin (AT), protein C antigen and activity, protein S antigen (total and free) and activity prior to being placed on the apheresis circuit and after completion of exchange in patients with SCD (0-21 years of age) undergoing chronic erythrocytapheresis who had a CVL (between January 1, 2009 and January 31, 2015). D-Dimer levels were obtained pre exchange only. Protein C and S levels were measured using ELISA based assays; protein C and S activities were measured using a clotting based assay and AT was measured using a chromogenic assay. The resulting levels, pre and post-erythrocytapheresis were analyzed using a paired nonparametric Wilcoxon rank test.
Results
Eleven patients were eligible for this study (8 females, 3 males). Median age at the time of erythrocytapheresis was 14 years (±3.65 SD) years. Indications for erythrocytapheresis included primary/ secondary stroke prevention or recurrent acute chest syndrome. All patients had bilateral CVLs in place. Four of the included patients had a history of VTE; 2 patients were on anticoagulation with low molecular weight heparin at the time of the study. The mean value for total protein S antigen (65u/dL; normal >72u/dL), free protein S antigen (53u/dL; normal >70u/dL), and protein S activity (51IU/mL; normal 65-138IU/ml) were all abnormal pre- erythrocytapheresis and decreased significantly following erythrocytapheresis (52u/dL, 44u/dL, and 44IU/mL respectively). Mean protein C antigen (71u/dL; normal >55u/dL), protein C activity (71%; normal 55-111%), and AT activity (104%; normal 77-132%) were within the normal range pre-erythrocytapheresis and decreased significantly post-erythrocytapheresis. We demonstrated significantly lower levels of protein C antigen (p=0.01), protein C activity (p=0.01), total protein S antigen (p=0.005), free protein S antigen (p=0.036), protein S activity (p=.04), and AT activity (p=.004) following erythrocytapheresis (Figure). D-Dimer levels were elevated in 6/11 patients (54.5%).
Conclusions
Pre- and post-erythrocytapheresis levels of natural endogenous anticoagulants investigated in a cohort of patients with SCD undergoing chronic erythrocytapheresis demonstrated that levels of all investigated proteins were significantly lower in patients following erythrocytapheresis. D-dimer levels were elevated in the majority of patients pre exchange but the importance of this finding is unclear. Given the relatively short half-life of the natural anticoagulants (2-3 hours for protein C and 36-60 hours for AT and protein S), it is unclear if this acute decrease of natural anticoagulants is clinically relevant. Further investigation is needed to determine if this acute decrease may contribute to an increased VTE risk in children with SCD undergoing apheresis.
Display omitted
Woods:Biogen: Other: Educational Grant. Dunn:Novo Nordisk: Consultancy, Other: Educational Grant; CSL Behring: Consultancy, Other: Data Safety Monitoring Board; Bayer: Consultancy, Other: educational grant; Biogen: Consultancy, Other: Educational grant, Research Funding; Baxalta: Consultancy, Other: educational grant, Research Funding; Ohio State University: Employment; Pfizer: Other: Grant Review Board.
At the Arts Academy, students will take core academic classes in the mornings and in the afternoons delve into the artistic endeavors, whether it's figure skating at the Steel Ice Center in ...Bethlehem, ballet dancing in the school's dance studios or painting in an art classroom. The school offers six tracks: dance, theater, vocal and instrumental music, visual arts, which includes painting and sculpting, and figure skating.
The developer previously promised to withdraw the projects after receiving approval for a rehabilitation center at the shuttered Synthetic Thread factory at 825 12th Ave. Now city officials are ...preparing a court appeal to challenge the validity of the zoning. cgallagher@mcall.com 610-820-6586 Credit: The Morning Call (Allentown, Pa.\n
Who am I to decide that Catholicism is better than Moravian or chocolate ice cream is better than vanilla?" The school board listed several reasons as to why the school shouldn't open in a former ...Penn State University building at 8380 Mohr Lane in Fogelsville, the desired location.